Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02408523




Registration number
NCT02408523
Ethics application status
Date submitted
31/03/2015
Date registered
3/04/2015
Date last updated
17/12/2020

Titles & IDs
Public title
A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
Scientific title
A Double-blind, Randomized, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy
Secondary ID [1] 0 0
2011-003100-21
Secondary ID [2] 0 0
SP0982
Universal Trial Number (UTN)
Trial acronym
VALOR
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Epilepsy 0 0
Condition category
Condition code
Neurological 0 0 0 0
Epilepsy
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Lacosamide Tablet
Treatment: Drugs - Lasosamide Oral Solution
Other interventions - Placebo Tablet
Other interventions - Placebo Oral Solution

Experimental: Lacosamide - Lacosamide 50 mg tablets: starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400 mg/day for adult subjects and pediatric subjects \>= 50 kg.

Lacosamide oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects \< 30 kg.)

Lasosamide oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30 kg to \< 50 kg.)

Placebo comparator: Placebo - Placebo 50 mg tablets: starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400mg/day for adult subjects and pediatric subjects \>= 50kg.

Placebo oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects \< 30kg.)

Placebo oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30kg to \< 50kg.)


Treatment: Drugs: Lacosamide Tablet
* Active Substance: Lacosamide
* Pharmaceutical Form: Film-coated Tablet
* Concentration: 50 mg
* Route of Administration: Oral use

Treatment: Drugs: Lasosamide Oral Solution
* Active Substance: Lacosamide
* Pharmaceutical Form: Oral Solution
* Concentration: 10 mg/ml
* Route of Administration: Oral use

Other interventions: Placebo Tablet
* Active Substance: Placebo
* Pharmaceutical Form: Film-coated Tablet
* Concentration: 50 mg
* Route of Administration: Oral use

Other interventions: Placebo Oral Solution
* Active Substance: Placebo
* Pharmaceutical Form: Oral Solution
* Concentration: 10 mg/ml
* Route of Administration: Oral use
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to the Second Primary Generalized Tonic Clonic (PGTC) Seizure During the 24-week Treatment Period From Visit 2 (Week 0) to Visit 10 (Week 24)
Timepoint [1] 0 0
During the Treatment Period from Visit 2 (Week 0) to Visit 10 (Week 24)
Secondary outcome [1] 0 0
Percentage of Participants With Seizure Freedom for Primary Generalized Tonic Clonic (PGTC) Seizures During the 24-week Treatment Period From Visit 2 (Week 0) to Visit 10 (Week 24)
Timepoint [1] 0 0
During the Treatment Period from Visit 2 (Week 0) to Visit 10 (Week 24)
Secondary outcome [2] 0 0
Time to the First Primary Generalized Tonic Clonic (PGTC) Seizure During the Treatment Period From Visit 2 (Week 0) to Visit 10 (Week 24)
Timepoint [2] 0 0
During the Treatment Period from Visit 2 (Week 0) to Visit 10 (Week 24)
Secondary outcome [3] 0 0
Percentage of Participants With at Least One Adverse Event (AE) as Reported Spontaneously by the Subject and/or Caregiver or Observed by the Investigator
Timepoint [3] 0 0
From Visit 1 (Week -4) to End of Study Period (up to Week 36)
Secondary outcome [4] 0 0
Plasma Concentrations of Lacosamide
Timepoint [4] 0 0
During the Treatment Period from Visit 2 (Week 0) to Visit 10 (Week 24)

Eligibility
Key inclusion criteria
* Subject with a confirmed diagnosis at least 24 weeks prior to Visit 1 and a disease onset prior to 30 years of age, consistent with idiopathic generalized epilepsy (IGE) experiencing primary generalized tonic-clonic (PGTC) seizures (Type IIE) that are classifiable according to the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures (ILAE, 1981)
* Subject has >=3 PGTC seizures during the 16-week Combined Baseline (12-week Historical Baseline plus 4-week Prospective Baseline)
* If a brain magnetic resonance imaging (MRI)/computed tomography (CT) scan has been performed, there must be no evidence of any progressive abnormality or any lesion likely to be associated with partial-onset seizures
* Subject has been maintained on a stable dose regimen of 1 to 2 non-benzodiazepine marketed antiepileptic drugs (AEDs) with no benzodiazepine AEDs OR 1 benzodiazepine marketed AED with 1 to 2 non benzodiazepine marketed AEDs for at least 28 days prior to Visit 1 with or without additional concurrent stable vagus nerve stimulation (VNS)
* Subjects are required to have had an electroencephalogram (EEG) report consistent with idiopathic generalized epilepsy (eg, generalized 3Hz epileptiform discharges and a normal EEG background) confirmed by a Central Reviewer
Minimum age
4 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Subject is receiving any investigational drugs or using any experimental devices in addition to Lacosamide (LCM)
* Subject meets the withdrawal criteria for SP0982 or is experiencing an ongoing serious adverse event (SAE)
* Subject has an active suicidal ideation as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the 'Since Last Visit' version of the Columbia-Suicide Severity Rating Scale (C-SSRS)
* Subject has >=2x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >ULN total bilirubin (>=1.5xULN total bilirubin if known Gilbert's syndrome). If subject has elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin <35%)

For randomized subjects with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be understood and recorded in the electronic case report form (eCRF).

If subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at screening, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject must be discussed with the Medical Monitor.

Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated once for confirmation. This includes re-screening.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/06/2019
Sample size
Target
Accrual to date
Final
242
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Sp0982 981 - Parkville
Recruitment hospital [2] 0 0
Sp0982 980 - Chatswood
Recruitment hospital [3] 0 0
Sp0982 985 - Heidelberg
Recruitment hospital [4] 0 0
Sp0982 986 - Parkville
Recruitment postcode(s) [1] 0 0
- Parkville
Recruitment postcode(s) [2] 0 0
- Chatswood
Recruitment postcode(s) [3] 0 0
- Heidelberg
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Idaho
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Washington
Country [16] 0 0
United States of America
State/province [16] 0 0
Wisconsin
Country [17] 0 0
Belgium
State/province [17] 0 0
Brussels
Country [18] 0 0
Belgium
State/province [18] 0 0
Gent
Country [19] 0 0
Belgium
State/province [19] 0 0
Leuven
Country [20] 0 0
Brazil
State/province [20] 0 0
Curitiba
Country [21] 0 0
Brazil
State/province [21] 0 0
Florianópolis
Country [22] 0 0
Brazil
State/province [22] 0 0
Passo Fundo
Country [23] 0 0
Brazil
State/province [23] 0 0
Porto Alegre
Country [24] 0 0
Brazil
State/province [24] 0 0
Rio De Janeiro
Country [25] 0 0
Brazil
State/province [25] 0 0
São Paulo
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Blagoevgrad
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Sofia
Country [28] 0 0
China
State/province [28] 0 0
Beijing
Country [29] 0 0
China
State/province [29] 0 0
Changchun
Country [30] 0 0
China
State/province [30] 0 0
Chongqing
Country [31] 0 0
China
State/province [31] 0 0
Fuzhou
Country [32] 0 0
China
State/province [32] 0 0
Hangzhou
Country [33] 0 0
China
State/province [33] 0 0
Shanghai
Country [34] 0 0
Czechia
State/province [34] 0 0
Ostrava poruba
Country [35] 0 0
Czechia
State/province [35] 0 0
Praha
Country [36] 0 0
Czechia
State/province [36] 0 0
Zlín
Country [37] 0 0
France
State/province [37] 0 0
Bron
Country [38] 0 0
France
State/province [38] 0 0
Lille Cedex
Country [39] 0 0
France
State/province [39] 0 0
Nancy
Country [40] 0 0
France
State/province [40] 0 0
Rennes Cedex 9
Country [41] 0 0
Germany
State/province [41] 0 0
Berlin
Country [42] 0 0
Germany
State/province [42] 0 0
Erlangen
Country [43] 0 0
Germany
State/province [43] 0 0
Freiburg
Country [44] 0 0
Germany
State/province [44] 0 0
Marburg
Country [45] 0 0
Germany
State/province [45] 0 0
Muenchen
Country [46] 0 0
Hungary
State/province [46] 0 0
Budapest
Country [47] 0 0
Hungary
State/province [47] 0 0
Szeged
Country [48] 0 0
Israel
State/province [48] 0 0
Re?ovot
Country [49] 0 0
Israel
State/province [49] 0 0
Tel HaShomer
Country [50] 0 0
Italy
State/province [50] 0 0
Torino
Country [51] 0 0
Japan
State/province [51] 0 0
Asaka
Country [52] 0 0
Japan
State/province [52] 0 0
Fukuoka-shi
Country [53] 0 0
Japan
State/province [53] 0 0
Gifu
Country [54] 0 0
Japan
State/province [54] 0 0
Hamamatsu
Country [55] 0 0
Japan
State/province [55] 0 0
Hiroshima
Country [56] 0 0
Japan
State/province [56] 0 0
Itami
Country [57] 0 0
Japan
State/province [57] 0 0
Kagoshima
Country [58] 0 0
Japan
State/province [58] 0 0
Kodaira
Country [59] 0 0
Japan
State/province [59] 0 0
Kokubunji
Country [60] 0 0
Japan
State/province [60] 0 0
Niigata
Country [61] 0 0
Japan
State/province [61] 0 0
Sapporo
Country [62] 0 0
Japan
State/province [62] 0 0
Shinjuku-Ku
Country [63] 0 0
Japan
State/province [63] 0 0
Shizuoka
Country [64] 0 0
Japan
State/province [64] 0 0
Omura
Country [65] 0 0
Korea, Republic of
State/province [65] 0 0
Daegu
Country [66] 0 0
Korea, Republic of
State/province [66] 0 0
Seoul
Country [67] 0 0
Mexico
State/province [67] 0 0
Guadalajara
Country [68] 0 0
Poland
State/province [68] 0 0
Czestochowa
Country [69] 0 0
Poland
State/province [69] 0 0
Gdansk
Country [70] 0 0
Poland
State/province [70] 0 0
Gdynia
Country [71] 0 0
Poland
State/province [71] 0 0
Gliwice
Country [72] 0 0
Poland
State/province [72] 0 0
Katowice
Country [73] 0 0
Poland
State/province [73] 0 0
Tyniec Maly
Country [74] 0 0
Poland
State/province [74] 0 0
Warszawa
Country [75] 0 0
Portugal
State/province [75] 0 0
Lisboa
Country [76] 0 0
Romania
State/province [76] 0 0
Iasi
Country [77] 0 0
Romania
State/province [77] 0 0
Timisoara
Country [78] 0 0
Russian Federation
State/province [78] 0 0
Ekaterinburg
Country [79] 0 0
Russian Federation
State/province [79] 0 0
Kazan
Country [80] 0 0
Russian Federation
State/province [80] 0 0
Pyatigorsk
Country [81] 0 0
Russian Federation
State/province [81] 0 0
Saint Petersburg
Country [82] 0 0
Russian Federation
State/province [82] 0 0
Samara
Country [83] 0 0
Russian Federation
State/province [83] 0 0
Smolensk
Country [84] 0 0
Slovakia
State/province [84] 0 0
Bardejov
Country [85] 0 0
Slovakia
State/province [85] 0 0
Hlohovec
Country [86] 0 0
Spain
State/province [86] 0 0
Barcelona
Country [87] 0 0
Spain
State/province [87] 0 0
Córdoba
Country [88] 0 0
Spain
State/province [88] 0 0
Madrid
Country [89] 0 0
Spain
State/province [89] 0 0
Málaga
Country [90] 0 0
Spain
State/province [90] 0 0
Sevilla
Country [91] 0 0
Taiwan
State/province [91] 0 0
Taichung
Country [92] 0 0
Taiwan
State/province [92] 0 0
Taipei

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
UCB BIOSCIENCES, Inc.
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Pharmaceutical Research Associates
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
UCB Cares
Address 0 0
+1 844 599 2273 (UCB)
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT02408523